Page last updated: 2024-10-15

dBET6

Cross-References

ID SourceID
PubMed CID121427831
CHEMBL ID4303781
CHEBI ID189651
SCHEMBL ID17859031

Synonyms (33)

Synonym
CHEBI:189651
S8762
SCHEMBL17859031
2-((s)-4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-n-(8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)octyl)acetamide
dbet 6
1950634-92-0
gtpl10534
dbet-6
CS-0047679
dbet6
HY-112588
2-((s)-4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-n-(8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)octyl)-acetamide
EX-A3094
CHEMBL4303781
AT14156
A935629
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-[8-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]oxy]acetyl]amino]octyl]-2,3,9-trimethyl-, (6s)-
us11059801, compound dbet6
bdbm511598
AKOS037653363
2-[(9s)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-n-[8-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]octyl]acetamide
2-((s)-4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-
f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-n-(8-(2-((2-(2,6-
dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-
yl)oxy)acetamido)octyl)acetamide
BD177448
DTXSID901022545
AC-35571
2-((s)-4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2- f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-n-(8-(2-((2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4- yl)oxy)acetamido)octyl)acetamide
n-(8-{2-[(9s)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0,trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}octyl)-2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1h-isoindol-4-yl]oxy}acetamide
BP-28374
n-(8-{2-[(9s)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0,2,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetamido}octyl)-2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1h-isoindol-4-yl]oxy}acetamide
EN300-23308290
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcription intermediary factor 1-alphaHomo sapiens (human)IC50 (µMol)1.96000.13581.837910.0000AID1619194
Bromodomain-containing protein 4Homo sapiens (human)IC50 (µMol)0.06540.00040.40329.0500AID1907440; AID1907441
E3 ubiquitin-protein ligase TRIM33Homo sapiens (human)IC50 (µMol)4.69000.23351.01654.6900AID1619193
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bromodomain-containing protein 4Homo sapiens (human)DC500.00510.00510.05330.1000AID1808926
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
transcription by RNA polymerase IITranscription intermediary factor 1-alphaHomo sapiens (human)
positive regulation of gene expressionTranscription intermediary factor 1-alphaHomo sapiens (human)
protein ubiquitinationTranscription intermediary factor 1-alphaHomo sapiens (human)
protein catabolic processTranscription intermediary factor 1-alphaHomo sapiens (human)
regulation of protein stabilityTranscription intermediary factor 1-alphaHomo sapiens (human)
regulation of apoptotic processTranscription intermediary factor 1-alphaHomo sapiens (human)
response to peptide hormoneTranscription intermediary factor 1-alphaHomo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription intermediary factor 1-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription intermediary factor 1-alphaHomo sapiens (human)
epithelial cell proliferationTranscription intermediary factor 1-alphaHomo sapiens (human)
negative regulation of epithelial cell proliferationTranscription intermediary factor 1-alphaHomo sapiens (human)
calcium ion homeostasisTranscription intermediary factor 1-alphaHomo sapiens (human)
regulation of vitamin D receptor signaling pathwayTranscription intermediary factor 1-alphaHomo sapiens (human)
cellular response to estrogen stimulusTranscription intermediary factor 1-alphaHomo sapiens (human)
regulation of signal transduction by p53 class mediatorTranscription intermediary factor 1-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
chromatin organizationBromodomain-containing protein 4Homo sapiens (human)
DNA damage responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
regulation of inflammatory responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
protein ubiquitinationE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwayE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
negative regulation of BMP signaling pathwayE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
negative regulation of DNA-templated transcriptionE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
methylated histone bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
p53 bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
chromatin bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
transcription coactivator activityTranscription intermediary factor 1-alphaHomo sapiens (human)
protein kinase activityTranscription intermediary factor 1-alphaHomo sapiens (human)
signaling receptor bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
protein bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
zinc ion bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
nuclear receptor bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
estrogen response element bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
ubiquitin protein ligase activityTranscription intermediary factor 1-alphaHomo sapiens (human)
lysine-acetylated histone bindingTranscription intermediary factor 1-alphaHomo sapiens (human)
transcription cis-regulatory region bindingBromodomain-containing protein 4Homo sapiens (human)
p53 bindingBromodomain-containing protein 4Homo sapiens (human)
chromatin bindingBromodomain-containing protein 4Homo sapiens (human)
transcription coregulator activityBromodomain-containing protein 4Homo sapiens (human)
transcription coactivator activityBromodomain-containing protein 4Homo sapiens (human)
protein bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityBromodomain-containing protein 4Homo sapiens (human)
enzyme bindingBromodomain-containing protein 4Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II C-terminal domain bindingBromodomain-containing protein 4Homo sapiens (human)
P-TEFb complex bindingBromodomain-containing protein 4Homo sapiens (human)
histone reader activityBromodomain-containing protein 4Homo sapiens (human)
DNA bindingE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
ubiquitin-protein transferase activityE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
protein bindingE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
zinc ion bindingE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
co-SMAD bindingE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
R-SMAD bindingE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
male germ cell nucleusTranscription intermediary factor 1-alphaHomo sapiens (human)
nucleusTranscription intermediary factor 1-alphaHomo sapiens (human)
nucleoplasmTranscription intermediary factor 1-alphaHomo sapiens (human)
perichromatin fibrilsTranscription intermediary factor 1-alphaHomo sapiens (human)
mitochondrionTranscription intermediary factor 1-alphaHomo sapiens (human)
cytosolTranscription intermediary factor 1-alphaHomo sapiens (human)
euchromatinTranscription intermediary factor 1-alphaHomo sapiens (human)
chromatinTranscription intermediary factor 1-alphaHomo sapiens (human)
condensed nuclear chromosomeBromodomain-containing protein 4Homo sapiens (human)
nucleusBromodomain-containing protein 4Homo sapiens (human)
nucleoplasmBromodomain-containing protein 4Homo sapiens (human)
nucleusE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
nucleoplasmE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
chromatinE3 ubiquitin-protein ligase TRIM33Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1907456Protac activity at BRD4 short isoform in human MV4-11 cells at 10 to 1000 nM measured after 4 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907442Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by CCK8 assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907452Anti-proliferative activity in human MV4-11 cells assessed as downregulation of c-myc levels at 10 to 1000 nM incubated for 4 hrs by western blot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907453Protac activity at BRD4 long isoform in human MV4-11 cells at 100 nM for 4 hrs in presence of MG132 by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907469Protac activity at BRD4 short isoform in human OCI-AML-3 cells assessed as recovery of BRD4S expression at 100 nM for 24 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907461Protac activity at BRD3 in human MV4-11 cells at 100 nM measured after 4 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1409608AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1907468Protac activity at BRD4 short isoform in human SKM-1 cells assessed as recovery of BRD4S expression at 100 nM for 24 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1409607IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1907463Protac activity at BRD4 long isoform in human MV4-11 cells at 100 nM for 4 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907443Cell cycle arrest in human MV4-11 cells assessed as accumulation at G2/M phase at 0.1 uM for 24 hrs by PI/RNase staining based flow cytometry analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1677585Metabolic stability in cryopreserved human hepatocytes assessed as half-life at 1 uM incubated for 4 hrs2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications.
AID1808926Induction of degradation of wildtype BRD4 BD1 (unknown origin) expressed in Flp293T cells coexpressing EGFP and mCherry incubated for 5 hrs by laser scanning fluorimetric assay2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Structure-Guided Design of a "Bump-and-Hole" Bromodomain-Based Degradation Tag.
AID1907455Protac activity at BRD4 long isoform in human MV4-11 cells at 10 to 1000 nM measured after 4 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907459Protac activity at BRD2 in human MV4-11 cells at 100 nM measured after 4 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1409611AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1907462Protac activity at BRD3 in human MV4-11 cells at 100 nM measured after 24 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907440Inhibition of BRD4-BD1 (unknown origin) preincubated for 30 mins followed by substrate addition and measured after 3 hr by HTRF assay2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1409613Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1907465Protac activity at BRD4 short isoform in human MV4-11 cells at 100 nM for 4 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907441Inhibition of BRD4-BD2 (unknown origin) preincubated for 30 mins followed by substrate addition and measured after 3 hr by HTRF2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907458Anti-proliferative activity in human MV4-11 cells assessed as downregulation of c-myc levels at 100 nM incubated for 24 hrs by western blot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907446Protac activity at BRD4 short isoform in human MV4-11 cells assessed as recovery of BRD4S expression at 100 nM for 12 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1409614Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound 2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1409609Cytotoxicity of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1907467Protac activity at BRD4 short isoform in human MV4-11 cells assessed as recovery of BRD4S expression at 100 nM for 24 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907445Protac activity at BRD4 long isoform in human MV4-11 cells at 100 nM measured upto 24 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907460Protac activity at BRD2 in human MV4-11 cells at 100 nM measured after 24 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907464Protac activity at BRD4 long isoform in human MV4-11 cells at 100 nM for 24 hrs by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
AID1907470Protac activity at BRD4 short isoform in human MV4-11 cells at 100 nM for 4 hrs in presence of MG132 by immunoblot analysis2022European journal of medicinal chemistry, Jun-05, Volume: 236Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's8 (100.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]